These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23737277)

  • 1. Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
    de Oliveira JM
    BMJ; 2013 Jun; 346():f3568. PubMed ID: 23737277
    [No Abstract]   [Full Text] [Related]  

  • 2. Should we be reassured about sitagliptin?
    Segal J
    BMJ; 2013 May; 346():f3051. PubMed ID: 23674336
    [No Abstract]   [Full Text] [Related]  

  • 3. Authors' reply to de Oliveira.
    Eurich DT;
    BMJ; 2013 Jun; 346():f3579. PubMed ID: 23737280
    [No Abstract]   [Full Text] [Related]  

  • 4. [Sitagliptin].
    Taéron C
    Rev Infirm; 2008 Oct; (144):46-8. PubMed ID: 19009789
    [No Abstract]   [Full Text] [Related]  

  • 5. [Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].
    Perusicová J
    Vnitr Lek; 2007 Oct; 53(10):1109-13. PubMed ID: 18072437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin: a viewpoint by Mark S. Kipnes.
    Kipnes MS
    Drugs; 2007; 67(4):598-9. PubMed ID: 17352517
    [No Abstract]   [Full Text] [Related]  

  • 7. [A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin)].
    Abel T; Fehér J
    Orv Hetil; 2010 Jun; 151(25):1012-6. PubMed ID: 20519186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypoglycemia in the diabetes treatment - risk minimization with dipeptidyl peptidase-4 inhibitors].
    Acuña C
    Drugs Today (Barc); 2010 Dec; 46 Suppl F():1-12. PubMed ID: 21240332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sitagliptin.
    Drucker D; Easley C; Kirkpatrick P
    Nat Rev Drug Discov; 2007 Feb; 6(2):109-10. PubMed ID: 17342863
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.
    Tremblay AJ; Lamarche B; Deacon CF; Weisnagel SJ; Couture P
    Diabetes Obes Metab; 2011 Apr; 13(4):366-73. PubMed ID: 21226820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Incretin enhancer: sitagliptin].
    Kondo M; Tanizawa Y
    Nihon Rinsho; 2011 May; 69(5):859-63. PubMed ID: 21595272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
    Bhatt DL; Cavender MA
    JACC Heart Fail; 2014 Dec; 2(6):583-5. PubMed ID: 24998081
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT; Simpson S; Senthilselvan A; Asche CV; Sandhu-Minhas JK; McAlister FA
    BMJ; 2013 Apr; 346():f2267. PubMed ID: 23618722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial therapy for type 2 diabetes. Examination of a combination approach.
    Henson K; Hight R; Welborn D; Wyatt S
    Adv Nurse Pract; 2009 Jun; 17(6):43-4. PubMed ID: 20000183
    [No Abstract]   [Full Text] [Related]  

  • 16. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
    Scheen AJ; Van Gaal LF
    Rev Med Liege; 2013 Oct; 68(10):504-10. PubMed ID: 24298724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin--another option for managing type 2 diabetes in dialysis patients?
    St Peter WL; Weinhandl ED; Flessner MF
    Am J Kidney Dis; 2013 Apr; 61(4):532-5. PubMed ID: 23497767
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database.
    Cai B; Katz L; Alexander CM; Williams-Herman D; Girman CJ
    Int J Clin Pract; 2010 Nov; 64(12):1601-8. PubMed ID: 20946268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary objective of study of sitagliptin in patients with ESRD on dialysis.
    Arjona Ferreira JC; Golm GT; Goldstein BJ
    Am J Kidney Dis; 2013 Sep; 62(3):642. PubMed ID: 23972060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.